3-6-06

Express Mail Label No.: EV 695510657 US

Date of Deposit: March 2, 2006

Attorney Docket No.: 23239-531 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANTS:

Stanton et al.

RIAL NUMBER:

10/826,077

EXAMINER:

Not Yet Assigned

FILING DATE:

April 15, 2004

ART UNIT:

1635

For:

APTAMER-TOXIN MOLECULES AND METHODS FOR USING

SAME

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;

2. Modified Form 1449/PTO (1 page), in duplicate; and

3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23239-531 CIP. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

or R. Elrifi, Reg. No. 39,529

Jennifer A. Karnakis, Reg. No. 53,097

Attorneys for Applicants c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241 Customer No. 30623

Date: March 2, 2006

Express Mail Label No.: EV 695510657 US

Date of Deposit: March 2, 2006 Attorney Docket No.: 23239-531 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANTS:

Stanton et al.

ERIAL NUMBER:

10/826,077

EXAMINER:

Jon Benjamin Ashen

FILING DATE:

April 15, 2004

ART UNIT:

1635

For:

APTAMER-TOXIN MOLECULES AND METHODS FOR USING

SAME

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the Supplementary European Office Search Report for EP 03 76 0481, mailed December 28, 2005, which is related to the above-identified case. Accordingly, no fee or certification is believed required. Copies of the references are not provided as they were previously cited and/or submitted to the USPTO in prior applications, Serial No. 10/600,007, filed June 18, 2003 and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the

APPLICANTS:

Stanton et al. 10/826,077

U.S.S.N.:

information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23239-531 CIP.

Respectfully submitted,

or R. Elrifi, Reg. No. 39,529

Jennifer A. Karnakis, Reg. No. 53,097 Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623 Tel: (617) 542-6000


Fax: (617) 542-2241

Date: March 2, 2006

TRA 2125449v.1

Express Mail Label: EV 695510657 US

Date of Deposit: March 2, 2006





Page 1 of 1
Attorney Docket No.: 23239-531 CIP

									1				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)							Application Numb	10/826,	10/826,077				
							Filing Date	April 15, 2004 Stanton 1635 Jon Benjamin Ashen 23239-531 CIP					
							First Named Inventor						
							Group Art Unit						
							Examiner Name						
							Attorney Docket Number						
	120	3:		o lead	U	.S. I	PATENT DOCUMENT	S	1 10	- 64	â		
Exam Initials	Cite No.)	U.S. Patent Document No.	Issue Date		Name of Patentee(s) or Applicant(s)		Class	Sub Class	Filing Date If Appropriate			
	Lor.			11.0	DUBL	ICUI	ED ADDI ICATION DO	OUNTENTO:	The second	- in the state of	h 1-1. 1720	. 53	
Exam	Cite		U.S. Published Publish				ED APPLICATION DOCUMENTS the me of Patentee(s) or Applicant(s)		Class	Sub	Filing Date		
Initials	No.		Application No.	Date					Class		if		
=-	1			6							App	ropriate	
	FOR		EIGN PATENT DOCUMENTS										
Exam	Cite					me d	of Patentee(s) or Applicant(s)		Date of	100 Co. 100 Co		lation	
Initials	No.		Office Number						Publication		Yes	Yes No	
Initials	No.		Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.										
Exam	Cite												
	*C8	Bodey et al. <i>Anticancer Res.</i> , 16:661-674 (1996)											
	*C8	Brody et al. Rev. Mol. Biotechnol., 74:5-13 (2000)											
	*C9	0	George, D. Ser	eorge, D. Sem. Oncol., 28(5 - Supl. 17):27-33 (2001)									
	*C91		Gilliland et al. Proc. Natl. Acad. Sci. USA, 77(8):4539-4543 (1980)										
	*C92		Jayasema, S. Clin. Chem., 45(9):1628-1650 (1999)										
	*C93		Lavrovsky et al. Biochem. Mol. Med., 62:11-22 (1997)										
	*C94		Pastan et al. Science, 254:1173-1177 (1991)										
	*C95		Pietras et al. Cancer Res., 61(7):2929-2934 (2000)										
	*C96		Pirker, R. J. Cancer Res. Clin. Oncol., 114(4):385-393 (1988)										
	*C97		Siegall, C. Cancer, 74(3):1006-1012 (1994)										
	*C98		Waldmann, T. Science, 252:1657-1661 (1991)										
	*C99		Supplementary European Search Report for EP 03 76 0481, mailed December 28, 2005.										
* A copy o 10/600,0 0 divisional)7, file	d Jun	ence is not provided te 18, 2003, and reli	as it was	previou	usly	cited by or submitted t r filing date under 35 L	to the office in a	prior applica	ation, Seria	ıl No.	ınd	
Examiner Signature								Date Considered		,			
								<u> </u>					